Conversion of shares - Correction

Conversion of shares - Correction

According to RaySearch's articles of association, owners of Class A
shares have the right to have such shares converted to Class B shares.
Conversion reduces the total number of votes in the company.

On June 29 RaySerach issued a press release regarding conversion of
shares in June. The information in the press release was correct but it
should have been issued on the last day of trading, June 30, and not on
June 29 which was the case. To ensure correct financial reporting, the
same information is therefore published again as stated below. No
conversion of shares has occurred in July.

In June, at the request of Bengt Lind, 1,061,577 Class A shares were
converted to Class B shares.
The total number of votes in the company thereafter amounts to
136,202,292.

The total number of registered shares in the company amounts to
34,282,773, of which 11,324,391 are Class A shares and 22,958,282 are
Class B shares.

About RaySearch
RaySearch Laboratories is a medical technology company that develops
advanced software solutions for improved radiation therapy of cancer.
RaySearch's products are mainly sold through license agreements with
leading partners such as Philips, Nucletron, IBA Dosimetry, Varian,
TomoTherapy and Siemens. To date, 15 products have been launched through
partners and RaySearch's software is used at some 1,800 clinics in more
than 30 countries. In addition, RaySearch offers the proprietary
treatment planning system RayStation® directly to clinics. RaySearch was
founded in 2000 as a spin-off from Karolinska Institutet in Stockholm
and the company is listed in the Small Cap segment on NASDAQ OMX
Stockholm.

For more information about RaySearch, visit
www.raysearchlabs.com (http://www.raysearchlabs.com/).

For further information, contact:
Anders Martin-Löf, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-545 061 30
anders.martin-lof@raysearchlabs.com (johan.lof@raysearchlabs.com)